Cargando…

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives

A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Villaverde, Ricardo, Vasquez-Chinchay, Fiorella, Rodriguez-Fernandez-Freire, Lourdes, C. Armario-Hita, Jose, Pérez-Gil, Amalia, Galán-Gutiérrez, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505180/
https://www.ncbi.nlm.nih.gov/pubmed/36143449
http://dx.doi.org/10.3390/life12091412
_version_ 1784796408174346240
author Ruiz-Villaverde, Ricardo
Vasquez-Chinchay, Fiorella
Rodriguez-Fernandez-Freire, Lourdes
C. Armario-Hita, Jose
Pérez-Gil, Amalia
Galán-Gutiérrez, Manuel
author_facet Ruiz-Villaverde, Ricardo
Vasquez-Chinchay, Fiorella
Rodriguez-Fernandez-Freire, Lourdes
C. Armario-Hita, Jose
Pérez-Gil, Amalia
Galán-Gutiérrez, Manuel
author_sort Ruiz-Villaverde, Ricardo
collection PubMed
description A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of a multicenter, observational study of real clinical practices including patients with moderate-to-severe plaque PSO undergoing treatment with Guselkumab (GUS). This cross-sectional analysis includes information on patients between February 2019 to February 2022. A SR is a patient that achieved a PASI = 0 at weeks 12 and 24. Analyses have been performed “as observed” using GraphPad Prism version 8.3.0 for Windows (GraphPad Software, San Diego, CA, USA, At baseline, the PASI is significantly correlated with VAS_pruritus, BSA, and DLQI, while DLQI is significantly correlated with VAS_pruritus. Significant correlations increase in number and magnitude over the follow-up time. In relation to the univariate logistic models carried out, only three variables showed a significant association with the super-responder variable: depression, VAS_pruritus, and DLQI.SR patients, who show a faster evolution in PASI and BSA improvement than non-SRs. Based on the results obtained, it would be possible to also include DLQI and VAS_pruritus in the broader concept of the SR.
format Online
Article
Text
id pubmed-9505180
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95051802022-09-24 Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives Ruiz-Villaverde, Ricardo Vasquez-Chinchay, Fiorella Rodriguez-Fernandez-Freire, Lourdes C. Armario-Hita, Jose Pérez-Gil, Amalia Galán-Gutiérrez, Manuel Life (Basel) Article A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of a multicenter, observational study of real clinical practices including patients with moderate-to-severe plaque PSO undergoing treatment with Guselkumab (GUS). This cross-sectional analysis includes information on patients between February 2019 to February 2022. A SR is a patient that achieved a PASI = 0 at weeks 12 and 24. Analyses have been performed “as observed” using GraphPad Prism version 8.3.0 for Windows (GraphPad Software, San Diego, CA, USA, At baseline, the PASI is significantly correlated with VAS_pruritus, BSA, and DLQI, while DLQI is significantly correlated with VAS_pruritus. Significant correlations increase in number and magnitude over the follow-up time. In relation to the univariate logistic models carried out, only three variables showed a significant association with the super-responder variable: depression, VAS_pruritus, and DLQI.SR patients, who show a faster evolution in PASI and BSA improvement than non-SRs. Based on the results obtained, it would be possible to also include DLQI and VAS_pruritus in the broader concept of the SR. MDPI 2022-09-10 /pmc/articles/PMC9505180/ /pubmed/36143449 http://dx.doi.org/10.3390/life12091412 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ruiz-Villaverde, Ricardo
Vasquez-Chinchay, Fiorella
Rodriguez-Fernandez-Freire, Lourdes
C. Armario-Hita, Jose
Pérez-Gil, Amalia
Galán-Gutiérrez, Manuel
Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
title Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
title_full Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
title_fullStr Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
title_full_unstemmed Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
title_short Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
title_sort super-responders in moderate–severe psoriasis under guselkumab treatment: myths, realities and future perspectives
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505180/
https://www.ncbi.nlm.nih.gov/pubmed/36143449
http://dx.doi.org/10.3390/life12091412
work_keys_str_mv AT ruizvillaverdericardo superrespondersinmoderateseverepsoriasisunderguselkumabtreatmentmythsrealitiesandfutureperspectives
AT vasquezchinchayfiorella superrespondersinmoderateseverepsoriasisunderguselkumabtreatmentmythsrealitiesandfutureperspectives
AT rodriguezfernandezfreirelourdes superrespondersinmoderateseverepsoriasisunderguselkumabtreatmentmythsrealitiesandfutureperspectives
AT carmariohitajose superrespondersinmoderateseverepsoriasisunderguselkumabtreatmentmythsrealitiesandfutureperspectives
AT perezgilamalia superrespondersinmoderateseverepsoriasisunderguselkumabtreatmentmythsrealitiesandfutureperspectives
AT galangutierrezmanuel superrespondersinmoderateseverepsoriasisunderguselkumabtreatmentmythsrealitiesandfutureperspectives